12月11日 - ** 药物开发商Tenaya Therapeutics的TNYA.O股价在延时交易中下跌12.5%至1.19美元
** TNYA在 (link) 公开发行普通股和认股权证；规模未披露
** Leerink Partners和Piper Sandler担任此次发行的联合账簿管理人
** 另外，TNYA公司宣布对罕见心脏病进行基因治疗的早期试验数据 (link)。
** 根据伦敦证券交易所的数据，TNYA有1.665亿股流通股，市值2.33亿美元。
** 覆盖该股的所有八家券商均给予 "买入 "或更高评级；PT中位数为5美元--数据由LSEG编制
** 截至上次收盘，TNYA股价年累计下跌4.9%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.